Clinical Trials
21 trialsNCT03008408 2026-05-22
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01068249 2026-04-30
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02397083 2026-02-13
LEVER
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02407509 2026-01-29
RAF/MEK
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT07318324 2026-01-06
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT01797523 2025-11-06
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting
NCT00087685 2025-05-01
RAD001 in Recurrent Endometrial Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02228681 2024-09-19
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT03154281 2024-08-01
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Avera McKennan Hospital & University Health Center
Phase 1 Completed
NCT00886691 2022-02-04
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT02283658 2020-10-23
Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Mayo Clinic
Phase 2 Completed
NCT03285802 2020-02-05
Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation
Greater Baltimore Medical Center
Phase 2/3 Completed
NCT01281514 2019-07-11
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer
Fox Chase Cancer Center
Phase 1 Completed
NCT01031381 2016-08-30
RADBEV
University of Pittsburgh
Phase 2 Completed
NCT02188550 2015-05-19
Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Sinai Hospital of Baltimore
Phase 2 Unknown
NCT01217177 2015-04-03
PHOENIX I
Novartis
Phase 1 Completed
NCT00870337 2014-10-29
ENDORAD
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT01149434 2014-10-06
Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
University of Utah
Phase 1/2 Terminated
NCT00967928 2014-02-14
Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
Accelerated Community Oncology Research Network
Phase 1 Withdrawn
NCT00703807 2014-01-14
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
Yale University
Phase 1 Completed